Last reviewed · How we verify

NCT03047187: SHOPS

The Functional Status of Anterior Cruciate Ligament Reconstruction (ACLR) Patients at Discharge From Rehabilitation

Status unknown Last updated 2 May 2017
What this trial tests

trial testing ACLR in Anterior Cruciate Ligament Injury in 25 participants. Status unknown.

Timeline
1 June 2017
Primary endpoint
1 April 2018
1 April 2018

Quick facts

Lead sponsorUniversity of Salford
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment25
Start date1 June 2017
Primary completion1 April 2018
Estimated completion1 April 2018

Drugs / interventions tested

Conditions studied

Sponsor

University of Salford

Who can join

18 and older, any sex, with Anterior Cruciate Ligament Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Objectives: 1. To examine the ability of ACLR patients at discharge from rehabilitation to perform a single-hop for distance. 2. To examine isometric muscle strength of ACLR patients at discharge from rehabilitation. 3. To examine ACLR patients' self-reported knee function at discharge from rehabilitation 4. To assess the psychological factors for ACLR patients at discharge from rehabilitation. 5. To correlate single-hop for distance with self-reported knee function, strength and psychological factors for ACLR patients at discharge from rehabilitation to discover whether any of these factors can predict the others.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Anterior Cruciate Ligament Injury

Currently open trials in the same condition.

Other University of Salford trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03047187.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing